Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn13 hours agoJustine RaBy Justine Ramore_vert
Biodexa gains license for polyposis asset as stock more than doubles14 hours agoJenna PhilpottBy Jenna Philpottmore_vert
“Profound concern” over WHO’s pandemic agreement, says AIDS charity15 hours agoRobert BarrieBy Robert Barriemore_vert
BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding15 hours agoAkosua MirekuBy Akosua Mirekumore_vert
Cell and gene therapy companies trip at scalability hurdle23 hours agoAkosua MirekuBy Akosua Mirekumore_vert
Pioneer Institute study finds IRA discourages non-opioid drug innovation4 days agoJenna PhilpottBy Jenna Philpottmore_vert
Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks4 days agomore_vert
Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy5 days agoJustine RaBy Justine Ramore_vert
Inflation Reduction Act to have knock on effect on R&D, say biotech experts5 days agoJenna PhilpottBy Jenna Philpottmore_vert
Novartis bags paediatric FDA label expansion for Lutathera6 days agoPhalguni DeswalBy Phalguni Deswalmore_vert
Investors advocate for early biotech partnerships for later deal success7 days agoAkosua MirekuBy Akosua Mirekumore_vert
Smaller regulators grasp innovation through international collaboration7 days agoAkosua MirekuBy Akosua Mirekumore_vert
EC approves BeiGene’s tislelizumab for three NSCLC indications7 days agoJustine RaBy Justine Ramore_vert
Spurred by rise in deals, experts say ADC innovation is set to advance8 days agoAkosua MirekuBy Akosua Mirekumore_vert
Hyundai to advance cancer study plans for niclosamide-based drug8 days agoJenna PhilpottBy Jenna Philpottmore_vert
Chiesi champions new inhaler propellant to reduce carbon footprint8 days agoPhalguni DeswalBy Phalguni Deswalmore_vert
Roche wins second FDA label expansion for Alecensa in NSCLC11 days agoPhalguni DeswalBy Phalguni Deswalmore_vert
Inhibikase sees “opportunity” in cardiopulmonary disease for IkT-001Pro11 days agoRobert BarrieBy Robert Barriemore_vert
Q&A: Cell and gene therapy value assessments need a rework to allow access11 days agoAkosua MirekuBy Akosua Mirekumore_vert
The next phase for mRNA: Looking beyond COVID-1911 days agoMiranda MclarenBy Miranda Mclarenmore_vert
“Lack of harmonisation in Europe” hindering gene therapy growth5 days agoRobert BarrieBy Robert Barriemore_vert
Chemomab touts study confirming CCL24 link to systemic sclerosis severity12 days agoJenna PhilpottBy Jenna Philpottmore_vert
OncoX inks licensing deal worth over $26m for NSCLC therapy12 days agoPhalguni DeswalBy Phalguni Deswalmore_vert
IGM and Sanofi collaboration will pivot to immunology and inflammation13 days agoJustine RaBy Justine Ramore_vert
Lexeo wins fast track designation for Friedreich’s ataxia gene therapy12 days agoJenna PhilpottBy Jenna Philpottmore_vert
Jardiance and Ofev propel Boehringer’s human pharma sales14 days agoAkosua MirekuBy Akosua Mirekumore_vert
Harnessing artificial intelligence and digital technologies across the biopharma value chain14 days agomore_vert
Two major breakthroughs in Fragile X Syndrome treatments14 days agoJenna PhilpottBy Jenna Philpottmore_vert
The cutting-edge monitoring technology that is transforming the future of clinical trials15 days agomore_vert
Marinus fails to meet early stopping criteria for status epilepticus trial15 days agoJustine RaBy Justine Ramore_vert
Soligenix bags orpan drug designation for Marburg virus vaccine15 days agoJenna PhilpottBy Jenna Philpottmore_vert